万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生>>传染免疫学
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生>>康复医学

OncoImmunology(研究方向:肿瘤学、免疫学) (官网投稿)

简介
  • 期刊简称待设置
  • 参考译名待设置
  • 核心类别 外文期刊,
  • IF影响因子待设置
  • 自引率待设置
  • 主要研究方向待设置

主要研究方向:

等待设置主要研究方向
待设置

OncoImmunology(月刊)杂志出版国家为美国,杂志涉及癌症的自然或治疗诱导的识别,以及肿瘤发生,炎症和免疫监视之间复杂的相互作用。我们现在创建一个新的,高调的杂志, OncoImmunology,专门处理肿瘤免疫学。
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊官网:

http://www.tandfonline.com/loi/koni20

3、期刊投稿:

https://oncoimm.msubmit.net/cgi-bin/main.plex

4、信息说明:本刊信息来源于网络,包括 SCI 收录核心期刊,增补期刊,期刊收录数据每年进行更新。本站是公益性网站,为网友投稿提供免费服务,由于受相关约束,我们不能提供相关期刊的影响因子、JCR期刊分区等数据供大家参考,造成不便,敬请谅解。

2017314日星期二

                    

 

Instructions to Authors

 

About the journal

 

OncoImmunology is an international, peer-reviewed journal publishing high-quality, original research. Please see the journal’s Aims & Scope for information about its focus and peer-review policy.

 

Preparing your paper

 

Submission types

 

OncoImmunology accepts the following types of submissions:

 

Research Papers/Reports. Research Papers or Reports should include the following sections in the following order:

 

Abstract: A single paragraph of fewer than 250 words. The primary goal of the abstract should be to make the general significance and conceptual advance of the work clearly accessible to a broad readership. References should not be cited in the abstract.

Introduction.

Results: Present results in a logical sequence in tables and illustrations. In the text, explain, emphasize or summarize the most important observations. Units of measurement should be expressed in accordance with Systeme International d'Unites (SI Units).

Discussion: Do not repeat in detail data given in the Results section. Emphasize the new and important aspects of the study. Relate observations to other relevant studies. On the basis of your findings (and others'), discuss possible implications/conclusions. When stating a new hypothesis, clearly label it as such.

Patients and Methods/Materials and Methods: Describe the selection of patients or experimental animals, including controls. Do not use patients' names or hospital numbers. Identify methods, apparatus (manufacturer's name and address) and procedures in sufficient detail to allow other workers to reproduce the results. Provide references and brief descriptions of methods that have been published. When using new methods, evaluate their advantages and limitations. Identify drugs and chemicals, including generic name, dosage and route(s) of administration.

Indicate whether the procedures were approved by the Ethics Committee of Human Experimentation in your country, or are in accordance with the Helsinki Declaration of 1975.

For reagents listed in the Materials and Methods section, the company that supplied the reagent and the catalog number should be listed in parentheses; do not list the company location.

References: No more than 85.

Figure legends.

Tables: Tables should be numbered consecutively with Arabic numerals and include descriptive titles and legends.

Methods Articles. Methods Articles must present original research that focuses mainly on a new experimental technique, procedure, or reagent that provides a significant advance in the field. These papers should follow the same structure as Research Papers or Short Articles. Please provide an abstract no longer than 100 words.

 

Brief Reports. Brief Reports should constitute unusually interesting data combined with a discussion of what the data might mean, or an explanation of why the data contradicts current paradigms. The primary goal of the abstract should be to make the general significance and conceptual advance of the work clearly accessible to a broad readership. Please include the following:

 

Abstract (one paragraph of fewer than 150 words)

Reviews. Reviews should be recognized as scholarly by specialists in the field being covered, but should also be written with a view to informing readers who are not specialized in that particular field, and should therefore be presented using simple prose. Please avoid excessive jargon and technical detail. Reviews should capture the broad developments and implications of recent work. The opening paragraph should make clear the general thrust of the review and provide a clear sense of why the review is now particularly appropriate. The concluding paragraph should provide the reader with an idea of how the field may develop or future problems to be overcome, but should not summarize the article.

 

To ensure that a review is likely to be accessible to as many readers as possible, it may be useful to ask a colleague from another discipline to read the review before submitting it. Submitted reviews are subject to the same page charges as full-length reports. Whether and how page charges will apply for commissioned reviews will be made clear when each review is commissioned.

Reviews should be up to 4,000 words and include an abstract of up to 100 words, a maximum of 4 figures/tables, and up to 80 references.

 

Author's View. An “Author's View” is a short piece that allows authors to describe a recent research paper from their lab published elsewhere. Please limit the paper to 900 words with a 50 word (approx) abstract. You may include up to 10 references and 1 figure. Please do not include any acknowledgements.

 

Author's Views will be invited by the Editors-in-Chief.

 

Points-of-View. Point-of-View articles should follow the same general guidelines as Reviews; however, there is considerable flexibility in their structure and content. These articles are intended to address controversial issues, express new ideas, or expand on work already published. They may contain new data, and like other submissions, are subject to peer review. Like Review articles, they should be accessible to a wide readership.

 

Point-of-View articles are generally commissioned from authors of the most important recent papers to offer additional insights. Unsolicited Point-of-View articles are also welcome, and these may discuss the authors' own work and/or recent significant advances in their field. Points-of-View may be up to 2,500 words and should also include an abstract of up to 50 words. They may include up to 2 figures/tables and no more than 30 references.

 

Responses to Point-of-View articles are encouraged and will also be published as Point-of-View articles. Responses may be considerably shorter and structured as letters.

 

Formatting and templates

 

Papers may be submitted in any standard file format, including Word and LaTeX. Figures should be saved separately from the text. The main document should be double-spaced, with one-inch margins on all sides, and all pages should be numbered consecutively. Text should appear in 12-point Times New Roman or other common 12-point font.

 

Style guidelines

 

Submissions to OncoImmunology should follow the style guidelines described in Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers (8th ed.). Merriam-Webster’s Collegiate Dictionary (11th ed.) should be consulted for spelling.

 

References

 

References should be presented in a separate section at the end of the document, in accordance with CSE Manual for Authors, Editors, and Publishers guidelines. The references should be listed and numbered based on the order of their first citation. Every reference should be assigned its own unique number. References should not be repeated in the list, with each mention given a different reference number, nor should multiple references be combined under a single reference number. Superscripted digits should be used for in-text citations. Superscripted citations should follow periods, commas, closed quotation marks, question marks, and exclamation points. Mention of a specific reference within the course of a sentence should be proceed by “ref.” (e.g., “For a review, see ref. 20” or “For reviews, see refs. 20–25”).

 

编辑委员会

 

总编辑

Lorenzo Galluzzi - 大学巴黎笛卡尔,巴黎,FR

Guido Kroemer - 巴黎大学笛卡尔,巴黎,FR

劳伦斯Zitvogel - INSERM,研究所Gustave RoussyVillejuifFR

 

编辑委员会

-皮埃尔·Abastado - 新加坡免疫网络,新加坡,SG

马修·阿尔伯特- 巴斯德研究所与INSERM,巴黎,FR

詹姆斯·艾利森- 纪念斯隆-凯特琳癌症中心,纽约市,纽约州美国

安娜C.安德森- 哈佛大学,剑桥大学,MA USA

罗恩N.阿普特- -古里安内盖夫大学,贝尔谢巴,IL

-玛哈Ayyoub 研究所德Cancerologie DE L'Ouest酒店- CLCC刘若英Gauducheau,南特,FR

让·弗朗索瓦·巴赫- 科学学院,巴黎, FR

Mary Helen Barcellos-Hoff - NYU Langone Medical CenterNew YorkNY,美国

菲利普Beckhove - 德国癌症研究中心,海德堡,DE

托马斯·布兰肯斯泰因- 马克斯-德尔布吕克-中心,柏林,DE

-伊夫·Blay - Üniversite电克劳德·伯纳德·里昂,里昂,FR

马克·博纳维尔- 中心德RECHERCHE EN Cancerologie南特,昂热,南特,FR

丽莎H.巴特菲尔德- 希尔曼癌症中心,匹兹堡,PAUSA

安妮Caignard - 研究所科钦,巴黎,FR

雪涛曹- 中国医学科学院,北京,CN

基娅拉卡斯泰利- 基金会IRCCS意大利国家代Tumori,米兰,IT

Federica Cavallo - 都灵大学,都灵,IT

Esteban Celis - Georgia Regents大学,亚特兰大,美国

Vincenzo Cerundolo - 牛津大学,牛津,英国

Lieping Chen - 耶鲁大学,纽黑文,美国CT

Yao-Tseng Chen - Cornell大学,纽约,美国

Aled Clayton - 卡迪夫大学,卡迪夫,英国

Mario Colombo - Fondazione IRCCS Istituto Nazionale dei Tumori,米兰,IT

Marco Colonna - 华盛顿大学医学院,圣路易斯,密苏里美国

George Coukos - 宾夕法尼亚大学,宾夕法尼亚州费城,美国

皮埃尔Coulie - 德迪夫研究所和鲁汶天主教大学,鲁汶,BE

马达夫Dhodapkar - 洛克菲勒大学,纽约,NYUSA

陈东- MD安德森癌症中心,休斯敦,得克萨斯州美国

格伦Dranoff - 达纳-法伯癌症研究所,马萨诸塞州波士顿美国

亚历山大Eggermont - 古斯塔夫·鲁西研究所,维勒瑞夫,FR

道格拉斯·费伦- 剑桥大学,英国剑桥

学院院长Felsher - 斯坦福大学,斯坦福大学,美国加利福尼亚州

卡尔G. Figdor - 奈梅亨中心分子生命科学,Nijmegan NL

Olivera J.芬兰 - 匹兹堡大学医学院,美国宾夕法尼亚州匹兹堡

Anthony Fodor - UNC医学院,美国北卡罗来纳州夏洛特

Guido Forni - 分子生物学中心,都灵,IT

Bernard A. Fox - Earle A. Chiles研究所,波特兰,OR美国

詹姆斯·福克斯- 技术,麻省理工学院剑桥,马萨诸塞州,美国

-伊恩·弗雷泽昆士兰大学,布里斯班,AU

-埃尔韦弗里德曼- 中心德RECHERCHE科德利埃宫,巴黎,FR

梅德一加布里洛维奇- H. Lee Moffitt癌症中心研究所,坦帕,FL美国

Thomas F. Gajewski - 芝加哥大学,芝加哥,美国

Giuseppe Giaccone - Lombardi综合癌症中心,乔治城大学,华盛顿特区,美国

Ellie Gilboa - 迈阿密大学,迈阿密,美国佛罗里达州

Sacha Gnjatic - Ludwig癌症研究所在纪念斯隆-凯特琳癌症中心,纽约,纽约州美国

F.斯蒂芬HODI - Dana-Farber癌症研究所,马萨诸塞州波士顿美国

阿克塞尔胡斯- 葛兰素史克,学院村,PA美国

安妮Hosmalin - 巴黎笛卡尔大学,巴黎,FR

德克积- 国家中心的肿瘤疾病,海德堡,DE

伊丽莎白M.雅菲- 约翰斯·霍普金斯大学,巴尔的摩,美国

埃尔克·耶格尔- Krankenhaus NORDWEST,法兰克福,DE

帕维尔Kalinski - 匹兹堡大学,匹兹堡,美国

克拉斯Kärre - 卡罗林斯卡研究所,斯德哥尔摩,SE

Howard L. Kaufman - Rutgers癌症研究所新泽西州新不伦瑞克,新泽西州

Rolf Kiessling - Karolinska研究所,斯德哥尔摩,SE

John Kirkwood - 匹兹堡大学医学院,匹兹堡,PA

伊娃克莱恩- 卡罗林斯卡研究所,斯德哥尔摩,SE

乔治·克莱恩- 卡罗林斯卡研究所,斯德哥尔摩,SE

亚历山大·克努特- 苏黎世大学医院,苏黎世,CH

彼得·克拉姆- 德国癌症研究中心,海德堡,DE

奥利弗·兰兹- 居里研究所,巴黎, FR

克莱尔刘易斯- 谢菲尔德大学的英国谢菲尔德

罗兰Liblau - INSERM UMR1043-CNRS UMR5282-Üniversite电图卢兹III FR图卢兹,

迈克尔- T.洛采匹兹堡大学,匹兹堡,PA美国

Enrico Lugli - Humanitas临床和研究中心,RozzanoIT

Jean-Pierre Mach - 洛桑大学,EpalingesCH

Francesco Marincola - NIH人类免疫中心,美国马里兰州贝塞斯达

Carlos Martinez - 科学与创新部,马德里,ES

法布里奇奥马泰- 因诺琴蒂基金会Superiore的迪SANITA,罗马,IT

伊格纳西奥Melero - 纳瓦拉大学,潘普洛纳,ES

-科内利斯J. Melief 莱顿大学医学中心,莱顿,NL

艾拉Mellman - 基因泰克公司,南旧金山,CA美国

Elizabeth Mittendorf - MD安德森癌症中心,美国德克萨斯州休斯顿

Lorenzo Moretta - Instanni Gianninia Gaslini GenovaIT

Sergei A. Nedospasov - Engelhardt俄罗斯科学院分子生物学研究所,莫斯科,RU

Kunle Odunsi - Roswell Park癌症研究所,布法罗,纽约美国

Hideho Okada - 匹兹堡大学医学院,匹兹堡,美国

Anna Karolina Palucka - 贝勒大学医学中心,达拉斯,美国

Giorgio Parmiani - San Raffaele基金会,米兰,IT

Marcus E.Peter - 西北大学Feinberg医学院,美国伊利诺伊州芝加哥

Kenneth J. Pienta - 约翰·霍普金斯医院,巴尔的摩,MD,美国

Angel Porgador - 本古里安内格夫大学,啤酒舍瓦,IL

乔治Prendergast - Lankenau研究所医学研究,WynnewoodPA USA

艾伦纯- 宾夕法尼亚大学,宾夕法尼亚州费城,美国

百利A.拉比诺维奇- 科学和技术研究全国委员会,布宜诺斯艾利斯,AR

汉斯-格奥尔格·Rammensee - 蒂宾根大学,蒂宾根,DE

David H制作。Raulet - 加州大学,伯克利分校,伯克利分校,美国加利福尼亚州

卡埃塔诺李嘉欣Ë索萨- 英国癌症研究中心,伦敦,英国

尼古拉斯Restifo - 美国国立卫生研究院,马里兰州贝塞斯达的美国

-安东尼·里瓦斯琼森综合癌症中心,洛杉矶,美国加利福尼亚州

帕乌拉RICCIARDI-Castagnoli酒店- 新加坡免疫学网络(SIgN),新加坡,SG

Naiyer Rizvi - 纪念斯隆凯特林癌症中心,纽约,纽约,美国

Bruce Robinson - 西澳大利亚大学,珀斯,澳大利亚

佩德罗罗梅罗 - 洛桑大学,洛桑

大学亚历山大Rudensky - 斯隆 - 凯特林癌症研究所,纽约,美国

Michel Sadelain - 纪念斯隆凯特林癌症中心,纽约,NY,美国

Shimon Sakaguchi - 京都大学前沿医学科学研究所,日本京都

Dolores J. Schendel - 德国环境健康研究中心,分子研究所免疫学,慕尼黑,DE

杰弗里Schlom - 美国国家癌症研究所,马里兰州贝塞斯达的美国

汉斯·施赖伯- 芝加哥大学,芝加哥,美国伊利诺斯州

罗伯特·施赖伯- 华盛顿大学,圣路易斯,密苏里州美国

格罗尔德舒勒- 埃尔兰根大学,埃尔兰根,DE

Ton Schumacher - 荷兰癌症研究所,荷兰阿姆斯特丹,荷兰

Barbara Seliger - UniversitätsklinikumHalle HalleDE

Padmanee Sharma - 德克萨斯大学,MD安德森癌症中心,休斯敦,美国

Hiroshi Shiku - 三重大学医学研究生院,

Bruno Silva-Santos - 医学研究所分子,里斯本,PT

Mark J. Smyth - Peter MacCallum癌症中心,墨尔本,AU

Daniel E. Speiser - Ludwig洛桑大学癌症研究所,洛桑大学,CH

普拉莫德ķ塔瓦- 医药,康涅狄格大学法学院法明顿,CT USA

-詹姆斯塔尔梅奇内布拉斯加大学医学中心,奥马哈,NE,美国

谷口维绍- 免疫学系,医学研究生院和学院医学院,东京,JP

埃里克Tartour - 总医院EUROPEEN Geoges蓬皮杜,巴黎,FR

阿兰·特劳特曼- 研究所科钦,巴黎,FR

乔治Trinchieri - 美国国家癌症研究所,弗雷德里克,MD USA

巴勃罗乌马尼亚- 罗氏Glycart AG,苏黎世,CH

达尼拉Valmori - 研究所德Cancerologie德升'Ouest - CLCC Rene Gauducheau ,南特, FRBenoîtVan

den Eynde - 路德维希癌症研究所,布鲁塞尔,BE

Pierre Van der Bruggen - Ludwig癌症研究所,布鲁塞尔BE

Sjoerd Van der Burg - Leiden大学医学中心, LeidenNL

理查德邪恶- 梅奥诊所,明尼苏达州罗切斯特美国

埃里克·维威耶- 中心德Immunologie马赛-吕米尼(CIML) ,马赛,FR

赫尔曼·瓦格纳- 技术大学沐尘,慕尼黑,DE

杰弗里·韦伯- 莫菲特癌症中心,坦帕,FL美国

Irving Weissman - 斯坦福大学医学院,斯坦福,加利福尼亚州

Theresa L Whiteside - 匹兹堡大学医学院,匹兹堡,美国

Ottmar D. Wiestler - 德国癌症研究中心(DKFZ),海德堡,德国

Jedd D. Wolchok - 纪念斯隆-凯特琳癌症中心,纽约,纽约州美国

卡西安怡- 弗雷德·哈钦森癌症研究中心,西雅图,华盛顿州


投稿问答最小化  关闭